Please select the option that best describes you:
Should maintenance rituximab be held due to COVID-19 in patients with advanced bulky follicular lymphoma who attain a PR/CR to weekly rituximab?
Answer from: Medical Oncologist at Academic Institution
Yes, hold rituximab. Independent of COVID-19, the RESORT trial demonstrated that retreatment on progression was equivalent to long-term maintenance with less exposure to the drug.
Sign in or Register to read more